In terms of overall metabolic improvement, SGLT-2 inhibitors reduce blood pressure, uric acid levels, and weight, improving patients’ metabolic state and significantly lowering cardiovascular disease risk. Here, SLC5A2 is linked to cardiovascular disorder.